<DOC>
	<DOCNO>NCT02358616</DOCNO>
	<brief_summary>This study primarily exploratory design identify factor may affect participant adherence study product VOICE , describe sexual behavior , anal sex , may effect product efficacy . As specific hypothesis test .</brief_summary>
	<brief_title>An Exploratory Study Potential Sources Efficacy Dilution VOICE Trial ( MTN-003 )</brief_title>
	<detailed_description>MTN-003D use qualitative in-depth interview and/or focus group discussion VOICE participant explore study product adherence and/or anal sex behavior great depth measure quantitatively trial participation . The study approach design encourage honesty minimize socially desirable response , may affect participant ' ability/willingness accurately report trial . An in-depth candid understand various behavioral factor contribute dilution efficacy may assist interpretation VOICE trial result inform future study . In light VOICE 's divergent result , MTN-003D explore potential factor may contribute efficacy dilution trial . MTN-003D , initially design early closure oral vaginal tenofovir arm , seek explore factor contribute dilution efficacy use qualitative method ( Stage 1 ) . Given subsequent release VOICE result February 2013 availability drug PK data , Stage 2 MTN-003D design explore factor influence adherence great depth , include HIV risk perception motivation join trial .</detailed_description>
	<criteria>Able willing perform study procedure Able willing provide inform consent one MTN003D study language Participated VOICE receive least three consecutive month study product time VOICE trial participation Stage 2 participant must pharmacokinetic data available Note : Women Stage 1 PK data available consider eligible Stage 2 Has condition , opinion Investigator Record ( IoR ) / designee : would preclude informed consent make study participation unsafe complicate interpretation study outcome data otherwise interfere achieve study objective .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2015</verification_date>
</DOC>